Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 301–400 of 1,000
Dendritic Cells in Cancer Immunotherapy
Vulink, A. J. E., Radford, K. J., Melief, C. J. M., & Hart, D. N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(07)99006-5 · Cited by 85
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
Wittig, B., Schmidt, M., Scheithauer, W., & Schmoll, H. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.002 · Cited by 78
Malaspina, T. S. D. S., Gasparoto, T. H., Nogueira, M. R. S., de Melo, E. J. F., Ikoma, M. R. V., Damante, J. H., Cavassani, K. A., Garlet, G. P., Silva, J. S., & Campanelli, A. P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1007-5 · Cited by 86
“These differences are relevant especially in CD4 T cells subset, since these cells are crucial in anti-tumor immune responses [24, 25] and a limitation in the TILs activation leads to increased tumor growth and, consequently, bad prognostic of tumors [25–27].”
BackgroundNeuraminidase-1: A novel therapeutic target in multistage tumorigenesis
Haxho, F., Neufeld, R. J., & Szewczuk, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.8396 · Cited by 80
“Evidence shows that once tumors develop, TAMs become immunosuppressive and have a defective ability (a) to release pro-inflammatory cytokines, (b) to present tumor-associated antigen, (c) to lyse tumor cells, and (d) to stimulate the antitumor functions of T cells and NK cells [192, 195, 196].”
BackgroundGrut, H., Solberg, S. K., Seierstad, T., Revheim, M. E., Egge, T. S., Larsen, S. G., Line, P., & Dueland, S. (2017) · British journal of surgery · doi:10.1002/bjs.10651 · Cited by 78
Langer, C. J. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000059 · Cited by 85
“The immune system plays a critical role in identifying and destroying foreign or abnormal cells in the body, including suppressing tumor growth.(14,15) Immunosurveillance is thought to involve both innate and adaptive immune mechanisms, including natural killer (NK) cells, CD8 + T cells, CD4 + T cells, and macrophages.”
BackgroundTrial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 86
“On one hand, components of the immune system, such a B lymphocytes and macrophages, have been shown to facilitate inflammation-driven carcinogenesis,(1-3) while others, such as CD8 T and natural killer (NK) cells, ensure a constant barrier against oncogenesis (immunosurveillance) that malignant precursors must break t…”
BackgroundZunino, B., Rubio‐Patiño, C., Villa, E., Meynet, O., Proïcs, E., Cornille, A., Pommier, S., Mondragón, L., Chiche, J., Bereder, J. M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.82 · Cited by 79
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
Harvey, R. D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.74 · Cited by 80
Peng, S., Hu, P., Xiao, Y.-T., Lü, W., Guo, D., Hu, S., Xie, J., Wang, M., Yu, W., Yang, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0299 · Cited by 85
“The nature of the tumor microenvironment (TME), regulated by dynamic tumor–immune cell interactions, can drastically impact tumor progression, tumor clearance, and immune response (10, 11).”
BackgroundEmerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
“The equilibrium phase is defined as a latency period between the elimination phase’s completion and the onset of clinically recognized malignant disease [6,10].”
BackgroundMetabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 87
Loumagne, L., Baudhuin, J., Favier, B., Montespan, F., Carosella, E. D., & Rouas‐Freiss, N. (2014) · International Journal of Cancer · doi:10.1002/ijc.28845 · Cited by 83
West, N. R., & Watson, P. H. (2010) · Oncogene · doi:10.1038/onc.2009.488 · Cited by 84
Deciphering the Message Broadcast by Tumor-Infiltrating Dendritic Cells
Karthaus, N., Torensma, R., & Tel, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.012 · Cited by 84
Gehrmann, M., Cervello, M., Montalto, G., Cappello, F., Gulino, A., Knape, C., Specht, H. M., & Multhoff, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00307 · Cited by 76
“The vesicular export of HSP70 in extracellular fluids was reported to stimulate effector mechanisms of the immune system (11, 12).”
BackgroundDarmanin, S., Chen, J., Zhao, S., Cui, H., Shirkoohi, R., Kubo, N., Kuge, Y., Tamaki, N., Nakagawa, K., Hamada, J.-I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4616 · Cited by 74
“C ancers exert systemic impact on immune cell function through various mechanisms (1, 2).”
BackgroundOncolytic Viral Therapy Using Reovirus
Thirukkumaran, C. M., & Morris, D. G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_12 · Cited by 77
Leite, M. L., da Cunha, N. B., & Costa, F. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.010 · Cited by 75
Maenhout, S. K., Van Lint, S., Emeagi, P. U., Thielemans, K., & Aerts, J. L. (2014) · International Journal of Cancer · doi:10.1002/ijc.28449 · Cited by 73
“, against mutated antigens), several inhibitory mechanisms have been identified that are responsible for actively quenching antitumor immune responses.(2) Defective T-cell function is a critical factor in immune escape in cancers.”
BackgroundAutophagy in natural and therapy-driven anticancer immunosurveillance
Pietrocola, F., Bravo-San Pedro, J. M., Galluzzi, L., & Kroemer, G. (2017) · Autophagy · doi:10.1080/15548627.2017.1310356 · Cited by 73
“Tumors elude immunosurveillance in a dual manner: (1) as cancer cell variants with limited immunogenicity are selected by the immune system (immunoediting), and/or (2) as neoplastic cells actively suppress tumor-targeting immune responses (immunosubversion).(8,9) Therefore, the (re)activation of adaptive immune respon…”
BackgroundCheckpoint inhibitor-induced uveitis: a case series
Conrady, C. D., Larochelle, M. B., Pecen, P. E., Palestine, A. G., Shakoor, A., & Singh, A. P. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3835-2 · Cited by 76
Nano delivery systems and cancer immunotherapy
Le, Q., Choi, J.-J., & Oh, Y. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-018-0399-z · Cited by 75
“Thus, a combination of oxaliplatin was reported to enhance the immunotherapy effect of CTLA-4 antibody (Pfirschke et al.”
BackgroundInfluentialPrognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients
Xu, W., Zhang, H., Xiong, J., Yang, X., Bai, Y., Lin, J., Long, J., Zheng, Y., Zhao, H., & Sang, X. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3281 · Cited by 75
Eyob, H., Ekiz, H. A., DeRose, Y. S., Waltz, S. E., Williams, M. A., & Welm, A. L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0480 · Cited by 73
“Hypoxia also suppresses T cell activity through expression of hypoxiainducible factor in macrophages (40).”
Cohen, M., Elkabets, M., Perlmutter, M., Porgador, A., Voronov, E., Apte, R. N., & Lichtenstein, R. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001635 · Cited by 73
“The immunoediting concept evolved from observations that tumors arising in immunodeficient mice present an immunogenic phenotype (16, 17).”
BackgroundTrial watch: Dendritic cell-based anticancer therapy
Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.963424 · Cited by 72
“DCs have a significant impact on oncogenesis, tumor progression and response to therapy.(35,65-68) This has been demonstrated not only in various preclinical tumor models involving alterations in the abundance or functional profile of precise DC subsets,(35,69-77) but also in a plethora of clinical studies,(78) correl…”
BackgroundCTLA-4 blockade and the renaissance of cancer immunotherapy
D, S. M. M., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 80
Aversa, I., Malanga, D., Fiume, G., & Palmieri, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072378 · Cited by 78
“T cells can identify and destroy nascent tumor cells by recognizing tumor-specific antigens presented by the major histocompatibility complex (MHC), a process known as cancer immunosurveillance [9]; in fact, evasion of immunosurveillance is considered a peculiar hallmark of cancer [10].”
BackgroundBreckpot, K., & Escors, D. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009789839156 · Cited by 76
“In fact, ERK negatively regulates DC maturation through secretion of immunosuppressive cytokines such as IL-10 and TGF-β [76, 77, 99-105].”
InfluentialTumor-Targeting NHC–Au(I) Complex Induces Immunogenic Cell Death in Hepatocellular Carcinoma
Yang, Z., Bian, M., Lv, L., Chang, X., Wen, Z., Li, F., Lu, Y., & Liu, W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01798 · Cited by 72
Ma, M. W., Medicherla, R. C., Qian, M., de Miera, E. V., Friedman, E. B., Berman, R. S., Shapiro, R. L., Pavlick, A. C., Ott, P. A., Bhardwaj, N., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.43 · Cited by 69
The tumour microenvironment: a novel target for cancer therapy
Hanna, E., Quick, J. S., & Libutti, S. K. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01471.x · Cited by 73
“The inability of immune surveillance to control malignant processes (Khong and Restifo, 2002; Ferris et al, 2006; Zitvogel et al, 2006), has lead researchers to discover ways to either augment the body’s natural immune system or to deliver various cells of the immune system to attack the tumour.”
BackgroundBerthel, A., Zoernig, I., Valous, N. A., Kahlert, C., Klupp, F., Ulrich, A. B., Weitz, J., Jaeger, D., & Halama, N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1286436 · Cited by 71
Nanbakhsh, A., Pochon, C., Mallavialle, A., Amsellem, S., Bourhis, J. H., & Chouaïb, S. (2014) · Blood · doi:10.1182/blood-2013-11-536219 · Cited by 75
“NK cells are a component of an innate immune system that play important roles as first line-defenders in the host response to tumors and infections, as well as in transplant rejection and in the development of tolerance.(22-27) Due to their strong ability to target tumor cells, NK cells have been described as promisin…”
BackgroundAutophagy Contributes to the Death/Survival Balance in Cancer PhotoDynamic Therapy
Inguscio, V., Panzarini, E., & Dini, L. (2012) · Cells · doi:10.3390/cells1030464 · Cited by 77
“their evolution to the malignant state, tumor cells evolve multiple ploys to ensure the survival [151], by acquiring the ability to replicate also in an inflamed microenvironment, to evade immune recognition and to suppress immune reactivity [152].”
BackgroundThe Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance
Hermann‐Kleiter, N., Klepsch, V., Wallner, S., Siegmund, K., Klepsch, S., Tuzlak, S., Villunger, A., Kaminski, S., Pfeifhofer‐Obermair, C., Gruber, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.035 · Cited by 71
Liang, J., Jin, X., Luo, G., Zhang, S., Huang, Q., Lin, Y.-T., Deng, X., Wang, J., Chen, W., & Zhang, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c05093 · Cited by 70
Wang, J., Shirota, Y., Bayık, D., Shirota, H., Tross, D., Gulley, J. L., Wood, L. V., Berzofsky, J. A., & Klinman, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402004 · Cited by 72
“C ancers survive by creating an immunosuppressive microenvironment that inhibits the activity of cytotoxic T and NK cells (1, 2).”
Background谷崎, 優., Kobayashi, A., Toujima, S., Shiro, M., Mizoguchi, M., Mabuchi, Y., Yagi, S., Minami, S., Takikawa, O., & Ino, K. (2014) · Cancer Science · doi:10.1111/cas.12445 · Cited by 71
Gerner, M. Y., Casey, K. A., & Mescher, M. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.155 · Cited by 71
“Considering that the steady-state tumor microenvironment does not contain strong stimuli for DC maturation, it becomes heavily dependent on CD4 T cell help, ablation of which would lead to tolerant antitumor CD8 T cell responses (44, 45).”
BackgroundAllen, C. T., Clavijo, P. E., Waes, C. V., & Chen, Z. (2015) · Cancers · doi:10.3390/cancers7040900 · Cited by 73
“This has been termed immunosubversion [49].”
May, K. F., Gulley, J. L., Drake, C. G., Dranoff, G., & Kantoff, P. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3402 · Cited by 73
“However, tumors have developed myriad ways to suppress and evade the immune system (1).”
Jeanbart, L., Kourtis, I. C., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1702-8 · Cited by 70
“Despite these efforts, many therapeutic modalities encounter limited success because of tumor-induced immune suppression and evasion mechanisms [6–9].”
BackgroundXu, B., Chen, L., Li, J., Zheng, X. W., Shi, L., Wu, C., & Jiang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12484 · Cited by 78
“The immune suppression of the tumors by immune cells and molecules of the tumor microenvironment has drawn much attention and recently shown promising immunotherapeutic results in various cancers [6].”
BackgroundAntitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Rivadeneira, D. B., & Delgoffe, G. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0894 · Cited by 67
“Identifying the mechanisms by which cancer cells escape immune surveillance is currently an expansive field of research in cancer immunology (5-7).”
BackgroundTripathi, R., Modur, V., Senovilla, L., Kroemer, G., & Komurov, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657374 · Cited by 68
“).(3) The strategy of re-activation of local tumor infiltrates by inhibiting the negative regulatory checkpoints, such asCTLA-4 andPD-1, onT-cells has had a remarkable success in the clinic.”
BackgroundLadoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 77
“The hazards ratios (HRs) with 95% confidence interval (CI) were calculated using univariate Cox proportional hazards regression modelling.”
BackgroundMethodTargeting microenvironment in cancer therapeutics
Martin, M., Wei, H., & Lu, T. (2016) · Oncotarget · doi:10.18632/oncotarget.9824 · Cited by 66
Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment
Kaimala, S., Al-Sbiei, A., Cabral-Marques, O., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00136 · Cited by 72
“, outgrowth of poorly immunogenic tumor-cell variants) impairs NK cell responses to tumors (34, 35).”
BackgroundBacteria and cancer: Different sides of the same coin
Laliani, G., Sorboni, S. G., Lari, R., Yaghoubi, A., Soleimanpour, S., Khazaei, M., Hasanian, S. M., & Avan, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117398 · Cited by 71
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 70
Cancer Immunosurveillance and Immunoediting by Natural Killer Cells
Gross, E., Sunwoo, J. B., & Bui, J. D. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000005 · Cited by 64
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Rivera Vargas, T., Benoit-Lizon, I., & Apetoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 65
Baxevanis, C. N., & Perez, S. A. (2015) · Vaccines · doi:10.3390/vaccines3030597 · Cited by 69
“actively suppress immune effector cells, and therefore evade immune-surveillance, by secretion of immunosuppressive factors or by recruitment of Tregs and MDSCs, which locally suppress the immune system [97–99].”
BackgroundClinical relevance of immune parameters in the tumor microenvironment of head and neck cancers
Wallis, S. P., Stafford, N. D., & Greenman, J. (2014) · Head & Neck · doi:10.1002/hed.23736 · Cited by 65
Evasion of tumours from the control of the immune system: consequences of brief encounters
Al-Tameemi, M. M. E., Chaplain, M. A. J., & d’Onofrio, A. (2012) · Biology Direct · doi:10.1186/1745-6150-7-31 · Cited by 64
“In general we share the opinion of [46], who stressed that recent progress in immunooncology has not influenced the way anti-cancer therapies are conceived and applied clinically.”
BackgroundMethodEdukulla, R., Woller, N., Mundt, B., Knocke, S., Gürlevik, E., Saborowski, M., Malek, N. P., Manns, M. P., Wirth, T. C., Kühnel, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1160 · Cited by 69
Roth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 70
“Because tumour initiation and progression are partially due to an escape to immunosurveillance system that fails to detect and destroy cancer cells [7], HCC seems to be a good candidate to immunostimulatory therapies aiming to restore anticancer immunity.”
BackgroundTherapeutic modulation of autophagy: which disease comes first?
Maiuri, M. C., & Kroemer, G. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0290-0 · Cited by 66
Farsam, V., Hassan, Z. M., Hosseini, A. Z., Noori, S., Mahdavi, M., & Ranjbar, M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.07.008 · Cited by 66
Nenclares, P., Bhide, S., Sandoval‐Insausti, H., Pialat, P.-M., Gunn, L., Melcher, A. A., Newbold, K. L., Nutting, C. M., & Harrington, K. J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.047 · Cited by 64
Differing Phenotypes between Intraepithelial and Stromal Lymphocytes in Early-Stage Tongue Cancer
Katou, F., Ohtani, H., Watanabe, Y., Nakayama, T., Yoshie, O., & Hashimoto, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2637 · Cited by 63
“CD8 cytotoxic T cells (CTL) and natural killer (NK) cells are the most likely effector cells for an effective antitumor immunity (1).”
BackgroundCancer immunoediting and “spontaneous” tumor regression
Sengupta, N., MacFie, T. S., MacDonald, T. T., Pennington, D. J., & Silver, A. R. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.10.001 · Cited by 72
“Evidence now exists that demonstrates the elimination phase of the immunoediting process before clinical symptoms are evident [73] and it is possible that a large number of potential tumors are eradicated in this way.”
BackgroundZhang, Y., Li, X., Zhang, J., & Liang, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.038 · Cited by 62
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 67
Li, Z., Wang, Q., Li, L., Chen, Y., Cui, J., Liu, M., Zhang, N., Liu, Z., Han, J., & Wang, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01236 · Cited by 62
Suppression of T cell responses in the tumor microenvironment
Frey, A. B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.096 · Cited by 61
“Accumulated data suggests that tumors use multiple mechaisms to escape antitumor immune responses that can be operative t different times during tumor growth and several may be contemoraneous, especially in later stages [18,19].”
BackgroundsiRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
Iwamura, K., Kato, T., Miyahara, Y., Naota, H., Mineno, J., Ikeda, H., & Shiku, H. (2011) · Gene Therapy · doi:10.1038/gt.2011.185 · Cited by 68
The multifaceted role of autophagy in tumor evasion from immune surveillance
Janji, B., Viry, E., Moussay, E., Paggetti, J., Arakelian, T., Mgrditchian, T., Messai, Y., Noman, M. Z., Moer, K. V., Hasmim, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7540 · Cited by 65
“Tumor avoidance of immunosurveillance [2], allowing tumor cells to escape anticancer immune responses or to actively suppress them [2, 3], has been firmly established as an additional hallmark of cancer.”
BackgroundZhu, Z., Mei, Z., Guo, Y., Wang, G., Wu, T., Cui, X., Huang, Z., Zhu, Y., Wen, D., Song, J., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy006 · Cited by 64
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 60
“Tumor microenvironment The tumor microenvironment (TME) is composed of immune cells, fibroblasts, blood vessels, and lymphatic tissues that surround tumor cells and has different abilities to induce favorable and unfavorable consequences of tumorigenesis [49, 50].”
Background18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
Hughes, D. J., Subesinghe, M., Taylor, B. P., Billè, A., Spicer, J. F., Papa, S., Goh, V., & Cook, G. (2022) · Radiology · doi:10.1148/radiol.212481 · Cited by 61
Gunaydin, G., Kesikli, S. A., & Guc, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1034918 · Cited by 59
Past, Present, and Future of Molecular and Cellular Oncology
Galluzzi, L., Vitale, I., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00001 · Cited by 66
“Escape can result from the loss of antigenic properties, a process called “immunoevasion,” or from active suppression of immune effectors, a process called “immunosubversion” (Zitvogel et al., 2006).”
BackgroundLu, Y., Zhang, M., Wang, S., Hong, B., Wang, Z., Li, H., Zheng, Y., Yang, J., Davis, R. E., Qian, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5229 · Cited by 58
Immunotherapy: A useful strategy to help combat multidrug resistance
Curiel, T. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.003 · Cited by 58
“It is now clear that tumors employ a myriad of active immune escape mechanisms to evade destruction by host immune defenses (Curiel, 2008; Zitvogel et al., 2006) (Fig.”
BackgroundInfluentialÖhman, J. N., Magnusson, B., Telemo, E., Jontell, M., & Hasséus, B. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02701.x · Cited by 58
Modeling Tumor Microenvironments In Vitro
Wu, M., & Swartz, M. A. (2014) · Journal of Biomechanical Engineering · doi:10.1115/1.4026447 · Cited by 58
Cannella, S., Santoro, A., Bruno, G., Pillon, M., Mussolin, L., Mangili, G., Rosolen, A., & Aricò, M. (2007) · Cancer · doi:10.1002/cncr.22718 · Cited by 59
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer
Gu, X., & Minko, T. (2024) · Cancers · doi:10.3390/cancers16081589 · Cited by 72
“This finding suggests that the biodegradable fluorescent polyplex NP could be a promising tool for early detection and treatment of PDAC.”
BackgroundJung, Y. W., Kim, Y. T., Kim, S. W., Kim, S., Kim, J., Cho, N. H., & Kim, J. W. (2009) · Reproductive Sciences · doi:10.1177/1933719109342131 · Cited by 57
“However, the HLA-G molecule is related to extrinsic mechanisms of carcinogenesis.(18) Therefore, there is little association between chemosensitivity and HLA-G expression.”
BackgroundTGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Young, K. H., Newell, P., Cottam, B., Friedman, D. J., Savage, T., Baird, J. R., Akporiaye, E. T., Gough, M. J., & Crittenden, M. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0207 · Cited by 61
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Killer dendritic cells and their potential for cancer immunotherapy
Larmonier, N., Fraszczak, J., Lakomy, D., Bonnotte, B., & Katsanis, E. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0736-1 · Cited by 61
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, Α. (2023) · Cancers · doi:10.3390/cancers15072101 · Cited by 76
“During the elimination phase, the balance is tipped towards anti-tumor immunity [19] due to the increased expression of neo-antigens in combination with the high frequency of major histocompatibility complex (MHC) class I molecules on the surface of”
BackgroundZhang, J., Qiao, X., Shi, H., Han, X., Liu, W., Tian, X., & Zeng, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-4349-3 · Cited by 61
“pose of metastasis, tumors have evolved different mechanisms to blunt immune response by which they could evade host immunosurveillance [3].”
BackgroundAutoantibodies Against Cancer Antigens
Gnjatic, S., Old, L. J., & Chen, Y. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-811-9_2 · Cited by 56
Sorensen, M. R., Holst, P. J., Steffensen, M. A., Christensen, J. P., & Thomsen, A. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.066 · Cited by 55
Walsh, M. P., Duncan, B. B., Larabee, S. M., Krauss, A. C., Davis, J. P. E., Cui, Y., Kim, S. Y., Guimond, M., Bachovchin, W. W., & Fry, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058860 · Cited by 56
“However, once progression occurs, the widely held assumption is that the tumor has evaded the immune response and that the host has become immunologically tolerant [3,4,5,6,7].”
BackgroundThe Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy
Krysan, K., Tran, L. M., Grimes, B. S., Fishbein, G. A., Seki, A., Gardner, B. K., Walser, T. C., Salehi‐Rad, R., Yanagawa, J., Lee, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0153 · Cited by 61
“In accord with the cancer immune surveillance theory, our current findings support the concept that the immune system is capable of recognizing cancer precursors (48, 49).”
ResultCXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo
Antonicelli, F. D., Lorin, J., Kurdykowski, S., Gangloff, S. C., Naour, R. L., Sallenave, J., Hornebeck, W., Grange, F., & Bernard, P. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10176.x · Cited by 57
Yoshida, N., Ino, K., Ishida, Y., Kajiyama, H., Yamamoto, E., Shibata, K., Terauchi, M., Nawa, A., Akimoto, H., Takikawa, O., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0991 · Cited by 65
Schildkopf, P., Frey, B., Mantel, F., Ott, O. J., Weiss, E., Sieber, R., Janko, C., Sauer, R., Fietkau, R., & Gaipl, U. S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.008 · Cited by 61
Tumor Microenvironmental Conversion of Natural Killer Cells into Myeloid-Derived Suppressor Cells
Park, Y.-J., Song, B., Kim, Y.-S., Kim, E., Lee, J.-M., Lee, G.-E., Kim, J., Kim, Y., Chang, W., & Kang, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0545 · Cited by 63
“1–3), to help cancer cells evade the attack by effector cells, leading to the subversion of the immune surveillance (3).”
BackgroundBurocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., & Piconese, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201141700 · Cited by 54
Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective
Axelrad, J. E., Roy, A., Lawlor, G. O., Korelitz, B. I., & Lichtiger, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10103 · Cited by 68
Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
Vacca, P., Munari, E., Tumino, N., Moretta, F., Pietra, G., Vitale, M., Zotto, G. D., Mariotti, F. R., Mingari, M. C., & Moretta, L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.11.004 · Cited by 58
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
“Kras; p53 lung adenocarcinoma,(128,129) MMTV-PyMT(130,131) or MMTV-neu(132) mammary carcinoma, Kras; p16; Pdx1-Cre pancreatic ductal adenocarcinoma(129,133)) might be more relevant because they have evolved ‘naturally’ and gone through immune selection and immune-editing processes.(134,135) Such engineered/autochthono…”
BackgroundThe danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“In their Darwinian struggle for immune evasion 74 and consequent unrestrained growth, human cancer cells do not only limit their anti-genicity (by avoiding the expression of dominant tumour antigens or by downregulating MHC class I expression altogether) 75,76 but also silence potentially…”
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.